Literature DB >> 18431261

Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis.

Shu-Min Lin1, Yu-Min Wang, Horng-Chyuan Lin, Kang-Yun Lee, Chien-Da Huang, Chien-Ying Liu, Chun-Hua Wang, Han-Pin Kuo.   

Abstract

OBJECTIVE: To determine serum concentrations of thrombomodulin, the marker of endothelial injury, in patients with sepsis-induced disseminated intravascular coagulation and multiple organ dysfunction syndrome and to investigate the independent association between this marker and the development of disseminated intravascular coagulation, multiple organ dysfunction syndrome, and mortality.
DESIGN: A prospective cohort study.
SETTING: A 37-bed intensive care unit of a tertiary care hospital. PATIENTS: One hundred consecutive patients with sepsis.
INTERVENTIONS: Serum thrombomodulin concentrations and the development of disseminated intravascular coagulation and multiple organ dysfunction syndrome were determined in patients on days 1 and 3 of sepsis. These data were used to determine an association between day 1 thrombomodulin concentrations and development of disseminated intravascular coagulation, multiple organ dysfunction syndrome, and mortality during intensive care unit stay. These connections were determined by the Cox proportional hazards model and plotting of receiver operating characteristic curves.
MEASUREMENTS AND MAIN RESULTS: Day 1 serum concentrations of thrombomodulin were higher in patients with disseminated intravascular coagulation (11.1 +/- 1.0 vs. 5.3 +/- 0.5 ng/mL; p < .0001) or multiple organ dysfunction syndrome (10.3 +/- 0.7 vs. 4.3 +/- 0.4 ng/mL; p < .0001) than those without, respectively. In patients with resolved disseminated intravascular coagulation (4.9 +/- 0.5 vs. 8.9 +/- 0.9 ng/mL, day 3 vs. day 1, p = .005) or multiple organ dysfunction syndrome (6.3 +/- 1.4 vs. 12.0 +/- 1.6 ng/mL, day 3 vs. day 1, p < .0001) on day 3 of sepsis, day 3 levels of thrombomodulin were down from day 1. Thrombomodulin concentration independently predicted the development of disseminated intravascular coagulation (hazard ratio 1.13, p < .0001), multiple organ dysfunction syndrome (hazard ratio 1.12, p < .0001), and mortality (hazard ratio 1.19, p < .0001) during intensive care unit stay. The area under the receiver operating characteristic curve showed that day 1 serum thrombomodulin levels had good discriminative power in predicting the development of disseminated intravascular coagulation (0.811), multiple organ dysfunction syndrome (0.896), and mortality (0.803) during intensive care unit stay.
CONCLUSIONS: Endothelial cell injury is critical in the progression from disseminated intravascular coagulation to multiple organ dysfunction syndrome and subsequent mortality in septic patients. Serum concentrations of thrombomodulin may be used in monitoring disseminated intravascular coagulation and multiple organ dysfunction syndrome in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18431261     DOI: 10.1097/CCM.0B013E31816537D8

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  34 in total

1.  Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome.

Authors:  Anil Sapru; Carolyn S Calfee; Kathleen D Liu; Kirsten Kangelaris; Helen Hansen; Ludmila Pawlikowska; Lorraine B Ware; Mustafa F Alkhouli; Jason Abbott; Jason Abbot; Michael A Matthay
Journal:  Intensive Care Med       Date:  2015-02-03       Impact factor: 17.440

Review 2.  Thrombomodulin and its role in inflammation.

Authors:  Edward M Conway
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

Review 3.  Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy.

Authors:  Anders Perner; Anthony C Gordon; Daniel De Backer; George Dimopoulos; James A Russell; Jeffrey Lipman; Jens-Ulrik Jensen; John Myburgh; Mervyn Singer; Rinaldo Bellomo; Timothy Walsh
Journal:  Intensive Care Med       Date:  2016-10-01       Impact factor: 17.440

Review 4.  Sepsis biomarkers: a review.

Authors:  Charalampos Pierrakos; Jean-Louis Vincent
Journal:  Crit Care       Date:  2010-02-09       Impact factor: 9.097

5.  Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.

Authors:  Ruinan Lu; Jingrui Sui; X Long Zheng
Journal:  Blood Adv       Date:  2020-11-10

6.  A high-fat diet delays plasmin generation in a thrombomodulin-dependent manner in mice.

Authors:  Adam Miszta; Anna K Kopec; Asmita Pant; Lori A Holle; James R Byrnes; Daniel A Lawrence; Kirk C Hansen; Matthew J Flick; James P Luyendyk; Bas de Laat; Alisa S Wolberg
Journal:  Blood       Date:  2020-05-07       Impact factor: 22.113

7.  Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia.

Authors:  Liv Andrés-Jensen; Kathrine Grell; Cecilie Utke Rank; Birgitte Klug Albertsen; Ruta Tuckuviene; Rikke Linnemann Nielsen; Line Stensig Lynggaard; Kirsten Brunsvig Jarvis; Petter Quist-Paulsen; Sonata Saulyte Trakymiene; Rūta Semaškevičienė; Kadri Saks; Olafur Gisli Jonsson; Thomas Leth Frandsen; Pär Ingemar Johansson; Kjeld Schmiegelow
Journal:  Leukemia       Date:  2021-08-13       Impact factor: 11.528

8.  Extravascular lung water correlates multiorgan dysfunction syndrome and mortality in sepsis.

Authors:  Fu-Tsai Chung; Horng-Chyuan Lin; Chih-Hsi Kuo; Chih-Teng Yu; Chun-Liang Chou; Kang-Yun Lee; Han-Pin Kuo; Shu-Min Lin
Journal:  PLoS One       Date:  2010-12-16       Impact factor: 3.240

9.  The immune response: targets for the treatment of severe sepsis.

Authors:  Aline M Bernard; Gordon R Bernard
Journal:  Int J Inflam       Date:  2012-12-03

Review 10.  Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals.

Authors:  Chad L Mayer; Caitlin S Leibowitz; Shinichiro Kurosawa; Deborah J Stearns-Kurosawa
Journal:  Toxins (Basel)       Date:  2012-11-08       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.